Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

Patient Relevant Outcomes Improvement Program in High Risk HR-positive Breast Cancer

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Inclusion Criteria:

• Femal patients age 18 or older at time of informed consent
• Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis)
• Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
• Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025

Exclusion Criteria:

• Locally advanced or metastatic breast cancer
• Male patients
• Patients with contraindication(s) for abemaciclib therapy according to SmPC